Jinling Pharmaceutical (000919.SZ) subsidiary's arotinolol hydrochloride API approved for marketing.
Jinling Pharmaceutical (000919.SZ) announced that its controlling subsidiary, Chizhou Dongsheng Pharmaceutical Co., Ltd., recently received the "Chemical API Marketing Application Approval Notice" for arotinolol hydrochloride issued by the National Medical Products Administration. Arotinolol hydrochloride is a receptor blocker that blocks both alpha and beta receptors, and its formulation products are mainly used to treat essential hypertension (mild to moderate), angina pectoris, and other diseases.
Jinling Pharmaceutical (000919.SZ) announced that its controlling subsidiary, Chizhou Dongsheng Pharmaceutical Co., Ltd., recently received the "Marketing Application Approval Notice for Chemical Active Pharmaceutical Ingredients" for arotinolol hydrochloride issued by the National Medical Products Administration. Arotinolol hydrochloride is a receptor blocker that blocks both alpha and beta receptors, and its formulation products are mainly used to treat essential hypertension (mild to moderate), angina pectoris, and other diseases.
Related Articles
HANSOH PHARMA (03692): Injection of Reconnective Votutamab (HS-20093) for the treatment of osteosarcoma included in the priority review and approval process of the National Medical Products Administration
.png)
CIMC ENRIC (03899) repurchased 200,000 shares for HK$1.456 million on September 22.
FIH (02038) spent HKD 948,300 to repurchase 60,000 shares on September 22.
HANSOH PHARMA (03692): Injection of Reconnective Votutamab (HS-20093) for the treatment of osteosarcoma included in the priority review and approval process of the National Medical Products Administration
CIMC ENRIC (03899) repurchased 200,000 shares for HK$1.456 million on September 22.
FIH (02038) spent HKD 948,300 to repurchase 60,000 shares on September 22.
